8QW6 image
Deposition Date 2023-10-18
Release Date 2023-12-06
Last Version Date 2024-10-02
Entry Detail
PDB ID:
8QW6
Keywords:
Title:
Crystal Structure of compound 3 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.29
R-Value Work:
0.25
R-Value Observed:
0.25
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:GTPase KRas
Gene (Uniprot):KRAS
Mutations:G12V, C118S
Chain IDs:D (auth: E), H (auth: A)
Chain Length:170
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:von Hippel-Lindau disease tumor suppressor
Gene (Uniprot):VHL
Mutations:Delta 1-53
Chain IDs:C (auth: F), G (auth: B)
Chain Length:162
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Elongin-C
Gene (Uniprot):ELOC
Mutations:delta 1-16
Chain IDs:B (auth: G), F (auth: C)
Chain Length:97
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Elongin-B
Gene (Uniprot):ELOB
Mutations:delta 105-118
Chain IDs:A (auth: H), E (auth: D)
Chain Length:104
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation

Abstact

Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.

Legend

Protein

Chemical

Disease

Primary Citation of related structures